MX2020013525A - Motivo de interaccion amiloide general. - Google Patents
Motivo de interaccion amiloide general.Info
- Publication number
- MX2020013525A MX2020013525A MX2020013525A MX2020013525A MX2020013525A MX 2020013525 A MX2020013525 A MX 2020013525A MX 2020013525 A MX2020013525 A MX 2020013525A MX 2020013525 A MX2020013525 A MX 2020013525A MX 2020013525 A MX2020013525 A MX 2020013525A
- Authority
- MX
- Mexico
- Prior art keywords
- amyloid
- gaim
- methods
- variants
- fusion proteins
- Prior art date
Links
- 230000003993 interaction Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 4
- 102000037865 fusion proteins Human genes 0.000 abstract 3
- 108020001507 fusion proteins Proteins 0.000 abstract 3
- 102000009091 Amyloidogenic Proteins Human genes 0.000 abstract 2
- 108010048112 Amyloidogenic Proteins Proteins 0.000 abstract 2
- 241001515965 unidentified phage Species 0.000 abstract 2
- 101710192393 Attachment protein G3P Proteins 0.000 abstract 1
- 101710179596 Gene 3 protein Proteins 0.000 abstract 1
- 230000006933 amyloid-beta aggregation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 238000007634 remodeling Methods 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/14011—Details ssDNA Bacteriophages
- C12N2795/14111—Inoviridae
- C12N2795/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/14011—Details ssDNA Bacteriophages
- C12N2795/14111—Inoviridae
- C12N2795/14133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862685757P | 2018-06-15 | 2018-06-15 | |
| US201862749499P | 2018-10-23 | 2018-10-23 | |
| PCT/US2019/037179 WO2019241628A1 (en) | 2018-06-15 | 2019-06-14 | General amyloid interaction motif (gaim) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020013525A true MX2020013525A (es) | 2021-02-26 |
Family
ID=67263052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020013525A MX2020013525A (es) | 2018-06-15 | 2019-06-14 | Motivo de interaccion amiloide general. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11692017B2 (enExample) |
| EP (2) | EP3806884B1 (enExample) |
| JP (1) | JP7549536B2 (enExample) |
| CN (1) | CN112672755A (enExample) |
| AU (1) | AU2019287623B2 (enExample) |
| BR (1) | BR112020025111A2 (enExample) |
| ES (1) | ES2960493T3 (enExample) |
| IL (1) | IL279333B2 (enExample) |
| MX (1) | MX2020013525A (enExample) |
| PL (1) | PL3806884T3 (enExample) |
| SG (1) | SG11202012091WA (enExample) |
| WO (1) | WO2019241628A1 (enExample) |
| ZA (1) | ZA202100071B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3806884B1 (en) * | 2018-06-15 | 2023-08-02 | Amyl Therapeutics | General amyloid interaction motif (gaim) |
| JP7505713B2 (ja) | 2019-02-22 | 2024-06-25 | ロヨラ メリーマウント ユニバーシティ | アミロイドペプチドバリアント |
| CN120641092A (zh) | 2022-12-02 | 2025-09-12 | 阿尔泽恩股份有限公司 | 用于用曲米沙特治疗神经变性病症的方法 |
| CN117343200B (zh) * | 2023-12-04 | 2024-01-30 | 北京质肽生物医药科技有限公司 | 一种包含淀粉样核心多肽的融合蛋白、制备方法及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
| US4215051A (en) | 1979-08-29 | 1980-07-29 | Standard Oil Company (Indiana) | Formation, purification and recovery of phthalic anhydride |
| CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| US8022270B2 (en) | 2000-07-31 | 2011-09-20 | Biolex Therapeutics, Inc. | Expression of biologically active polypeptides in duckweed |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| EP1673395A1 (en) | 2003-10-15 | 2006-06-28 | PDL BioPharma, Inc. | Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig |
| US9493515B2 (en) * | 2011-11-29 | 2016-11-15 | Proclara Biosciences, Inc. | Bacteriophage gene 3 protein compositions and use as amyloid binding agents |
| EA033666B1 (ru) * | 2012-10-02 | 2019-11-14 | Proclara Biosciences Inc | Амилоидсвязывающие белки и их применение |
| JP2016526044A (ja) * | 2013-05-28 | 2016-09-01 | ニューロファージ ファーマシューティカルズ， インコーポレイテッド | 低減された免疫原性を有する修飾されたバクテリオファージｇ３ｐアミノ酸配列を含むポリペプチド |
| KR20170085132A (ko) | 2014-12-03 | 2017-07-21 | 프로클라라 바이오사이언시즈, 인크. | 글리코실화 신호가 결핍된 변형된 박테리오파지 ｇ3ｐ 아미노산 서열을 포함하는 폴리펩티드 |
| EP3806884B1 (en) * | 2018-06-15 | 2023-08-02 | Amyl Therapeutics | General amyloid interaction motif (gaim) |
-
2019
- 2019-06-14 EP EP19739769.8A patent/EP3806884B1/en active Active
- 2019-06-14 WO PCT/US2019/037179 patent/WO2019241628A1/en not_active Ceased
- 2019-06-14 MX MX2020013525A patent/MX2020013525A/es unknown
- 2019-06-14 ES ES19739769T patent/ES2960493T3/es active Active
- 2019-06-14 EP EP23188404.0A patent/EP4389154A3/en active Pending
- 2019-06-14 CN CN201980049538.2A patent/CN112672755A/zh active Pending
- 2019-06-14 AU AU2019287623A patent/AU2019287623B2/en active Active
- 2019-06-14 US US17/251,351 patent/US11692017B2/en active Active
- 2019-06-14 PL PL19739769.8T patent/PL3806884T3/pl unknown
- 2019-06-14 SG SG11202012091WA patent/SG11202012091WA/en unknown
- 2019-06-14 JP JP2020569166A patent/JP7549536B2/ja active Active
- 2019-06-14 BR BR112020025111-9A patent/BR112020025111A2/pt unknown
-
2020
- 2020-12-09 IL IL279333A patent/IL279333B2/en unknown
-
2021
- 2021-01-05 ZA ZA2021/00071A patent/ZA202100071B/en unknown
-
2023
- 2023-05-19 US US18/320,697 patent/US12247055B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US12247055B2 (en) | 2025-03-11 |
| EP4389154A2 (en) | 2024-06-26 |
| SG11202012091WA (en) | 2021-01-28 |
| IL279333B2 (en) | 2023-06-01 |
| IL279333A (en) | 2021-01-31 |
| US11692017B2 (en) | 2023-07-04 |
| CA3102841A1 (en) | 2019-12-19 |
| US20210246179A1 (en) | 2021-08-12 |
| EP3806884C0 (en) | 2023-08-02 |
| WO2019241628A1 (en) | 2019-12-19 |
| ES2960493T3 (es) | 2024-03-05 |
| JP2021527407A (ja) | 2021-10-14 |
| BR112020025111A2 (pt) | 2021-04-06 |
| ZA202100071B (en) | 2023-04-26 |
| EP3806884B1 (en) | 2023-08-02 |
| AU2019287623B2 (en) | 2024-11-07 |
| JP7549536B2 (ja) | 2024-09-11 |
| EP3806884A1 (en) | 2021-04-21 |
| EP4389154A3 (en) | 2024-11-13 |
| AU2019287623A1 (en) | 2021-01-07 |
| US20230279064A1 (en) | 2023-09-07 |
| CN112672755A (zh) | 2021-04-16 |
| PL3806884T3 (pl) | 2023-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4389154A3 (en) | General amyloid interaction motif (gaim) | |
| Schneider et al. | Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments | |
| CN109937252A (zh) | 重组dna聚合酶 | |
| JP2014193892A5 (enExample) | ||
| JP2015212284A5 (enExample) | ||
| MX2020007882A (es) | Variantes fc con unión mejorada a fcrn y semivida prolongada. | |
| JP2019214579A5 (enExample) | ||
| Slomnicki et al. | A putative role of the Amyloid Precursor Protein Intracellular Domain (AICD) in transcription | |
| AR108442A1 (es) | Proteínas de fusión gdf15 y usos de estas | |
| JP2019514367A5 (enExample) | ||
| NO20082890L (no) | Anti-A-beta-globulomer-antistoff,antigenbindende enheter derav, tilsv hybridomer, nukleinsyrer, vektorer, vertsceller,fr.mater for fremst. av antistoffene, sammensetn. omf. antistoffene, anv. av antistoffene samt fremg.mater ved bruk av antistoffene | |
| Takano et al. | Prefoldin prevents aggregation of α-synuclein | |
| JP2018531624A5 (enExample) | ||
| CN110036108A (zh) | 一种细菌β-1,3-葡聚糖酶及其编码基因与应用 | |
| JP2023537070A5 (enExample) | ||
| JP2018186833A5 (enExample) | ||
| JP2020517643A5 (enExample) | ||
| JP2016537981A5 (enExample) | ||
| BR112017017609A2 (pt) | proteína de fusão fc, e, composição farmacêutica. | |
| JP2019512693A5 (enExample) | ||
| Boddapati et al. | Bispecific tandem single chain antibody simultaneously inhibits β-secretase and promotes α-secretase processing of AβPP | |
| CN110049994A (zh) | 一种缀合物及其应用 | |
| JP2018508571A5 (enExample) | ||
| MX2018003162A (es) | Variante en el numero de copias que genera resistencia a virus. | |
| EP1984013A4 (en) | CST II MODIFICATIONS FOR INCREASED PROTEIN EXPRESSION |